CrestPoint Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

CrestPoint Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-3,800	Closed	-$533K	–	225
2017 Q3	$533K	Sell	3,800 -200	-5%	-$27.2K	0.24%	142
2017 Q2	$487K	Buy	+4,000	New	+$466K	0.23%	143
2016 Q4	–	Sell	-2,400	Closed	-$294K	–	232
2016 Q3	$294K	Sell	2,400 -100	-4%	-$12.9K	0.15%	183
2016 Q2	$292K	Hold	2,500	–	–	0.16%	172
2016 Q1	$348K	Buy	2,500 +200	+9%	+$29.4K	0.19%	158
2015 Q4	$439K	Hold	2,300	–	–	0.25%	124
2015 Q3	$360K	Buy	+2,300	New	+$420K	0.21%	145
2015 Q1	–	Sell	-1,200	Closed	-$222K	–	254
2014 Q4	$222K	Sell	1,200 -100	-8%	-$18.5K	0.12%	210
2014 Q3	$216K	Sell	1,300 -2,000	-61%	-$328K	0.13%	201
2014 Q2	$516K	Buy	3,300 +400	+14%	+$63.2K	0.3%	117
2014 Q1	$441K	Hold	2,900	–	–	0.27%	127
2013 Q4	$385K	Buy	+2,900	New	+$348K	0.25%	131

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CrestPoint Capital Management's ALXN Position: Q4 2017 in Review

CrestPoint Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2017, closing a stake of 3,800 shares — an estimated $533K sold.

CrestPoint Capital Management first reported a position in ALXN in Q4 2013 and held it in 12 quarters. The position peaked at $533K in Q3 2017. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

CrestPoint Capital Management reported no remaining Alexion Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
CrestPoint Capital Management sold 3,800 Alexion Pharmaceuticals shares in Q4 2017, an estimated $533K.
CrestPoint Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 12 quarters.
CrestPoint Capital Management's Alexion Pharmaceuticals position peaked at $533K in Q3 2017.
587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on CrestPoint Capital Management's 13F filing for Q4 2017, filed 17 Jan 2018.